Related Experiment Video
Updated: May 8, 2026
05:44
Formation of Dispersible Taohong Siwu Tablets
Published on: February 3, 2023
Formulation and Evaluation of Alstonia boonei Stem Bark Powder Tablets
Salome A Chime1, E C Ugwuoke, I V Onyishi
1Department of Pharmaceutical Technology and Industrial Pharmacy, University of Nigeria, Nsukka 410 001, Nigeria.
Indian Journal of Pharmaceutical Sciences
|September 11, 2013
Summary
This study formulated Alstonia boonei stem bark into tablets using various binders. Tablets with acacia and gelatine binders met disintegration standards, unlike those with sodium carboxymethyl cellulose.
Area of Science:
- Pharmacognosy and Pharmaceutical Technology
- Phytochemical analysis of medicinal plants
- Drug formulation and delivery systems
Background:
- Alstonia boonei stem bark is traditionally used in medicine.
- Investigating its phytochemical constituents and pharmaceutical properties is crucial.
- Developing stable and effective dosage forms is a key pharmaceutical goal.
Purpose of the Study:
- To formulate Alstonia boonei dried stem bark powder into tablets using wet granulation.
- To evaluate the phytochemical profile of Alstonia boonei.
- To assess the quality and performance of the formulated tablets.
Main Methods:
- Wet granulation method using acacia, gelatine, and sodium carboxymethyl cellulose (SCMC) as binders at varying concentrations (1-8% w/w).
- Phytochemical screening of Alstonia boonei stem bark.
- Micromeritic properties evaluation of granules.
- Tablet evaluation including weight uniformity, hardness, friability, and disintegration time.
Main Results:
- Phytochemical analysis revealed the presence of alkaloids, tannins, steroids, saponins, glycosides, flavonoids, and terpenoids; anthraquinones and acidic compounds were absent.
- Granules exhibited good flowability.
- Tablets formulated with 1-4% w/w acacia and gelatine met British Pharmacopoeial specifications for weight uniformity, hardness, and friability.
- Tablets formulated with SCMC (1-8% w/w) and 8% w/w acacia/gelatine failed disintegration tests.
Conclusions:
- Alstonia boonei stem bark contains valuable phytochemicals.
- Acacia and gelatine at lower concentrations (1-4% w/w) are suitable binders for Alstonia boonei tablet formulation.
- Higher concentrations of SCMC and acacia/gelatine negatively impact tablet disintegration.
Related Concept Videos
01:18Formulation and Manufacturing Process: Physical Attributes of Generic Tablets and Capsules
Bioequivalence in generic drugs, such as tablets and capsules, refers to their pharmaceutical equivalence to the brand-name counterparts. However, for therapeutic equivalence, manufacturers must also consider physical attributes like size, shape, and weight (FDA Guidance for Industry, December 2003). Discrepancies in these aspects could impact patient compliance and cause medication errors. For instance, swallowing difficulties, often experienced with larger tablets or capsules, can lead to...
01:28Factors Influencing Drug Absorption: Pharmaceutical Parameters
Solid dosage forms such as tablets and capsules undergo rigorous manufacturing processes to ensure stability and effectiveness. Their dissolution and absorption properties are influenced significantly by the choice of excipients (inactive ingredients that serve various roles in the formulation), and the methodology applied during production. The manufacturing parameters, such as compression force and granulation techniques, significantly affect dissolution rates. Elevated compression forces...
01:27Pharmaceutical Alternatives: Polymorphic Form-Related and Particle Size-Related Therapeutic Nonequivalence
Changes in polymorphic forms can significantly influence the bioavailability of poorly soluble drugs. Although the FDA defines pharmaceutical equivalence based on having the same active ingredient, dosage form, and route of administration, it does not automatically disqualify products with different polymorphic forms. This means two products with different polymorphs can still be deemed pharmaceutically equivalent. However, polymorphic differences can affect properties like wettability,...
01:05Bioavailability Enhancement: Drug Stability Enhancement and GI Retention
Improving a drug's stability in the gastrointestinal (GI) tract is paramount for enhancing its bioavailability and therapeutic effectiveness. Various strategies are employed to protect the drug from the harsh gastric milieu and to ensure its release and absorption at the desired site within the GI tract.Polymer coatings are one such method used to shield drugs from the stomach's acidic environment. By preventing premature drug release, these coatings improve the bioavailability of unstable...
01:29Clinically Relevant Drug Product Specifications: Methods of Establishment
Product specifications define the acceptable quality of a pharmaceutical product by ensuring identity, purity, potency, and strength. These specifications serve as benchmarks during development, manufacturing, and post-approval quality control. Clinically relevant specifications are particularly important because they directly relate to a drug's safety and efficacy in clinical use.Dissolution studies are critical biopharmaceutic tools that link in vitro behavior to in vivo performance. They...
01:23Oral Drug Delivery Systems: Introduction
Oral drug delivery is the most common route of administration due to its convenience, cost-effectiveness, and high patient compliance. It enables precise formulation to ensure proper drug dosage and bioavailability. The development of oral dosage forms considers drug properties such as solubility, stability, and absorption to optimize therapeutic efficacy.Tablets, capsules, liquids, and chewable formulations enhance drug stability, mask undesirable tastes, and improve patient experience.